These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16677415)

  • 21. Small tyrosine kinase inhibitors as key molecules in the expression of metalloproteinases by solid tumors.
    Stahtea XN; Kousidou OCh; Roussidis AE; Tzanakakis GN; Karamanos NK
    Connect Tissue Res; 2008; 49(3):211-4. PubMed ID: 18661345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of receptor tyrosine kinases in combination with chemotherapy for the treatment of breast cancer.
    Moulder SL; Craft BS; Hortobagyi GN
    Anticancer Agents Med Chem; 2008 Jun; 8(5):481-7. PubMed ID: 18537531
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
    Engelman JA; Settleman J
    Curr Opin Genet Dev; 2008 Feb; 18(1):73-9. PubMed ID: 18325754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sunitinib malate and multiple receptor tyrosine kinases inhibitors: are they also novel drugs for chronic and neurophatic pain?
    Di Lorenzo L
    J Clin Oncol; 2007 Jul; 25(19):2858-9; author reply 2859-61. PubMed ID: 17602094
    [No Abstract]   [Full Text] [Related]  

  • 25. Hope without hype: EML4-ALK inhibition for treatment of lung cancer.
    Govindan R
    Lancet Oncol; 2011 Oct; 12(11):983-4. PubMed ID: 21933750
    [No Abstract]   [Full Text] [Related]  

  • 26. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications.
    Camorani S; Crescenzi E; Fedele M; Cerchia L
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):263-277. PubMed ID: 29574128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer.
    Katayama R
    Pharmacol Ther; 2017 Sep; 177():1-8. PubMed ID: 28185914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Antineoplastic agents targeting tyrosine kinases].
    Guren TK; Christoffersen T; Thoresen GH; Wisløff F; Dajani O; Tveit KM
    Tidsskr Nor Laegeforen; 2005 Nov; 125(22):3115-9. PubMed ID: 16299568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural studies of full-length receptor tyrosine kinases and their implications for drug design.
    Bajinting A; Ng HL
    Adv Protein Chem Struct Biol; 2021; 124():311-336. PubMed ID: 33632469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting ERBB receptors in cancer.
    Hynes NE
    Recent Results Cancer Res; 2007; 172():45-57. PubMed ID: 17607935
    [No Abstract]   [Full Text] [Related]  

  • 32. Forthcoming receptor tyrosine kinase inhibitors.
    Choong NW; Cohen EE
    Expert Opin Ther Targets; 2006 Dec; 10(6):793-7. PubMed ID: 17105367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stocking oncology's medicine cabinet.
    Kiberstis PA; Travis J
    Science; 2017 Mar; 355(6330):1142-1143. PubMed ID: 28302820
    [No Abstract]   [Full Text] [Related]  

  • 34. Targeting the cancer kinome through polypharmacology.
    Knight ZA; Lin H; Shokat KM
    Nat Rev Cancer; 2010 Feb; 10(2):130-7. PubMed ID: 20094047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PET Imaging of Receptor Tyrosine Kinases in Cancer.
    Wei W; Ni D; Ehlerding EB; Luo QY; Cai W
    Mol Cancer Ther; 2018 Aug; 17(8):1625-1636. PubMed ID: 30068751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology.
    Naito Y; Mishima S; Akagi K; Igarashi A; Ikeda M; Okano S; Kato S; Takano T; Tsuchihara K; Terashima K; Nishihara H; Nishiyama H; Hiyama E; Hirasawa A; Hosoi H; Maeda O; Yatabe Y; Okamoto W; Ono S; Kajiyama H; Nagashima F; Hatanaka Y; Miyachi M; Kodera Y; Yoshino T; Taniguchi H
    Int J Clin Oncol; 2020 Mar; 25(3):403-417. PubMed ID: 31974683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful targeted therapies for hepatocellular carcinoma: are we really getting there?
    Zhu AX
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):499-505. PubMed ID: 18402516
    [No Abstract]   [Full Text] [Related]  

  • 38. Kinases as targets in the treatment of solid tumors.
    Giamas G; Man YL; Hirner H; Bischof J; Kramer K; Khan K; Ahmed SS; Stebbing J; Knippschild U
    Cell Signal; 2010 Jul; 22(7):984-1002. PubMed ID: 20096351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib.
    Miyamoto S; Ikushima S; Ono R; Awano N; Kondo K; Furuhata Y; Fukumoto K; Kumasaka T
    Jpn J Clin Oncol; 2016 Feb; 46(2):170-3. PubMed ID: 26613679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.
    Montor WR; Salas AROSE; Melo FHM
    Mol Cancer; 2018 Feb; 17(1):55. PubMed ID: 29455659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.